Now covered by Medicare for all intermediate-risk prostate cancer patients



The Oncotype DX Genomic Prostate Score assay is fully covered by Medicare for patients with:

Gleason Score 4+3
or lower

Stage T2
or lower

PSA 20 ng/mL
or lower



Effective Date:

Effective now



Make more confident decisions about active surveillance and treatment intensity with the Oncotype DX GPS assay.


Actionable risk assessments for more informed treatment decisions

  • Predictive of Prostate Cancer Death and Metastasis within 10 years of receiving radical prostatectomy1
  • Predictive of Adverse Pathology2,3 the most immediate and actionable endpoint when making treatment decisions*
  • Developed, Validated and Studied in over 5,000 patients1-15
  • Medicare-Coverage for use in patients with NCCN very low-, low- and intermediate-risk prostate cancer
  • Included in NCCN Guidelines® as an option to help guide management decisions16

* Adverse pathology is provided for patients with Gleason 3+3 and 3+4 disease

  1. Van Den Eeden et al. Eur Urol. 2017.
  2. Klein et al. Eur Urol. 2014.
  3. Cullen et al. Eur Urol. 2015.
  4. Badani et al. Urol Pract. 2015.
  5. Albala et al. Rev Urol. 2016.
  6. Dall’Era et al. Urol Pract. 2015.
  7. Knezevic et al. BMC Genomics. 2013.
  8. Lynch et al. Am J Manage Care 2018.
  9. Brand et al. Urology. 2016.
  10. Bonham et al. USCAP 2016.
  11. Salmasi et al. J Urol. 2018.
  12. Eure et al. Urology. 2017.
  13. Eure et al. AUA 2017.
  14. Leapman et al. PloS One. 2017.
  15. Cullen et al. Urology. 2020.
  16. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.2.2020.

NCCN and NCCN Guidelines are registered trademarks of the National Comprehensive Cancer Network. NCCN does not endorse any therapy or product.

Making cancer care smarter.™

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.